Plasma homocysteine and risk of mild cognitive impairment

Dementia and Geriatric Cognitive Disorders

Volumn 27, Issue 1, 2009, Pages 11-17

  Reitz, Christiane ^a,b   Tang, Ming Xin ^a,c   Miller, Joshua ^d   Green, Ralph ^d   Luchsinger, José A ^a,b,c,e  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b University of California ^*  (United States)

^c Columbia University ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Dementia; Homocysteine; Mild cognitive impairment

Indexed keywords

CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

AGED; AMINO ACID BLOOD LEVEL; AMNESIA; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DEMENTIA; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ETHNIC GROUP; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; HYPERTENSION; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SMOKING; STROKE; VITAMIN BLOOD LEVEL;

AGE OF ONSET; AGED; AMNESIA; APOLIPOPROTEINS E; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; LONGITUDINAL STUDIES; MALE; RISK;

EID: 57649083123     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000182421     Document Type: Article

References (54)

1. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342.
2. Luchsinger JA, Mayeux R: Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004;6:261-266.
3. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD: Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-232.
4. Hankey GJ: Is plasma homocysteine a modifiable risk factor for stroke? Nat Clin Pract 2006;2:26-33.
5. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
6. Zylberstein DE, Bengtsson C, Bjorkelund C, Landaas S, Sundh V, Thelle D, Lissner L: Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004;109:601-606.
7. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
8. Ariogul S, Cankurtaran M, Dagli N, Khalil M, Yavuz B: Vitamin B 12 , folate, homocysteine and dementia: are they really related? Arch Gerontol Geriatr 2005;40:139-146.
9. Gunstad J, Bausserman L, Paul RH, Tate DF, Hoth K, Poppas A, Jefferson AL, Cohen RA: C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci 2006;13:540-546.
10. Haan MN, Miller JW, Aiello AE, Whitmer RA, Jagust WJ, Mungas DM, Allen LH, Green R: Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr 2007;85:511-517.
11. 12, and folic acid and the risk of cognitive decline in old age: the Leiden 85-Plus Study. Am J Clin Nutr 2005;82:866-871.
12. Seshadri S: Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimers Dis 2006;9:393-398.
13. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
14. Luchsinger JA, Tang MX, Miller J, Green R, Mehta PD, Mayeux R: Relation of plasma homocysteine to plasma amyloid β levels. Neurochem Res 2007;32:775-781.
15. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R: Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004;62:1972-1976.
16. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
17. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
18. Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF: Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59:1594-1599.
19. Luis CA, Barker WW, Loewenstein DA, Crum TA, Rogaeva E, Kawarai T, St George-Hyslop P, Duara R: Conversion to dementia among two groups with cognitive impairment. A preliminary report. Dement Geriatr Cogn Disord 2004;18:307-313.
20. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA: Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007;64:1734-1740.
21. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B, Mayeux R: The APOE-ε4 allele and the risk of Alzheimer disease among African-Americans, Whites, and Hispanics. JAMA 1998;279:751-755.
22. Stern Y, Andrews H, Pittman J, Sano M, Tatemichi T, Lantigua R, Mayeux R: Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49:453-460.
23. Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, DCAPA.
24. Manly JJ, Bell-McGinty S, Tang MX, Schupf N, Stern Y, Mayeux R: Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 2005;62:1739-1746.
25. Gilfix BM, Blank DW, Rosenblatt DS: Novel reductant for determination of total plasma homocysteine. Clin Chem 1997;43:687-688.
26. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
27. Hatano S: Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541-553.
28. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-1222.
29. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, Breteler MM: Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002;51:285-289.
30. Den Heijer T, Vermeer SE, Clarke R, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM: Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003;126:170-175.
31. Selhub J, Bagley LC, Miller J, Rosenberg ICH: B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000;71:614S-620S.
32. 6, and B 12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 2005;118:161-167.
33. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP: Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920-6926.
34. Parsons RB, Waring RH, Ramsden DB, Williams AC: In vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology 1998;19:599-603.
35. Miller AL: The methionine-homocysteine cycle and its effects on cognitive diseases. Altern Med Rev 2003;8:7-19.
36. Dufouil C, Alperovitch A, Ducros V, Tzourio C: Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 2003;53:214-221.
37. Tucker KL, Qiao N, Scott T, Rosenberg I, Spiro A, 3rd: High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr 2005;82:627-635.
38. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F: Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005;82:636-643.
39. Schafer JH, Glass TA, Bolla KI, Mintz M, Jedlicka AE, Schwartz BS: Homocysteine and cognitive function in a population-based study of older adults. J Am Geriatr Soc 2005;53:381-388.
40. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM: Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999;150:283-289.
41. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
42. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R: Mild cognitive impairment: directions for future research. Neurology 2003;61:438-444.
43. Manly J, Bell-McGinty S, Tang M-X, Schupf N, Stern Y, Mayeux R: Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol 2005;62 1739-1746.
44. Luchsinger JA, Reitz C, Patel B, Tang M-X, Manly JJ, Mayeux R: Relation of diabetes to mild cognitive impairment. Arch Neurol 2007;64:570-575.
45. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635-641.
46. 6, and vascular disease in AD patients. Neurology 2002;58:1471-1475.
47. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM: A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006;354:2764-2772.
48. 12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006;84:361-370.
49. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P: Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double-blind, controlled trial. Lancet 2007;369:208-216.
50. 12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007;85:193-200.
51. 12 intake and cognitive decline among community-dwelling older persons. Arch Neurol 2005;62:641-645.
52. Luchsinger JA: Folate, related vitamins and risk of Alzheimer's disease. Expert Rev Endocrinol Metab 2007;2:559-561.
53. Clarke R, Woodhouse P, Ulvik A, Frost C, Sherliker P, Refsum H, Ueland PM, Khaw KT: Variability and determinants of total homocysteine concentrations in plasma in an elderly population. Clin Chem 1998;44:102-107.
54. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, Eckfeldt JH: Short-term and long-term variability of plasma homocysteine measurement. Clin Chem 1997;43:141-145.